A study of RO7790121 for moderate to severe rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have moderate to severe rheumatoid arthritis with at least 6 swollen and 6 tender joints.
- You have tried at least one standard disease-modifying antirheumatic drug (DMARD) like methotrexate and it did not work well enough or caused side effects.
- You have not failed more than two TNF inhibitors or JAK inhibitors.
- You have not used other biologic drugs (except TNF inhibitors) or rituximab in the past.
- You do not have other inflammatory joint diseases, serious infections, or a history of cancer (except some skin cancers).
- You have not had steroid injections in the last 8 weeks or major surgery in the last 6 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This trial tests different targeted treatments for people with rheumatoid arthritis who have tried one or two biologic or targeted synthetic drugs but still have symptoms. You need to be taking a stable dose of methotrexate.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This trial tests an experimental drug for people with rheumatoid arthritis who have not had success with other treatments. It aims to see if the drug can help reduce joint pain and swelling.
This trial studies an add-on treatment approach for rheumatoid arthritis (RA) in adults whose symptoms did not improve with standard “first-line” medicines. It may help people who still have active RA after trying certain disease-modifying drugs.
This study tests a new investigational drug called SR-878 for people with rheumatoid arthritis. It aims to see if the drug is safe and tolerable. You may join if you are between 18 and 60, have RA for at least 3 months, and take a stable dose of methotrexate.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.